What Was Approved?
The FDA approved Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms due to menopause.
Vasomotor symptoms include hot flashes and night sweats, which can significantly affect sleep and quality of life.
How Does Lynkuet Work?
Lynkuet is a non-hormonal treatment.
It works by targeting neurokinin pathways involved in the brain’s regulation of body temperature.
This gives patients another option beyond traditional menopausal hormone therapy.
How Is Lynkuet Taken?
Lynkuet is taken by mouth once daily, usually at bedtime.
It may be taken with or without food. In some patients taking certain interacting medicines, the dose may need to be reduced.
Who Is It For?
Lynkuet is intended for adults experiencing moderate to severe hot flashes due to menopause.
Whether it is appropriate depends on the patient’s medical history, other medications, and individual treatment goals.
Why Is This Approval Important?
Hot flashes are among the most common and disruptive symptoms of menopause.
The approval of Lynkuet expands the number of non-hormonal treatment options available for patients who may not want or may not be candidates for hormone therapy.
What Should Patients Discuss With Their Healthcare Provider?
Patients should review:
- Other prescription and over-the-counter medications
- Possible drug interactions
- Side effects
- Liver or other medical conditions
- Whether hormonal or non-hormonal treatment is more appropriate
Bottom Line
Lynkuet (elinzanetant) is a newly approved non-hormonal prescription option for moderate to severe menopausal hot flashes.
Its approval gives patients another treatment choice for managing vasomotor symptoms associated with menopause.
Sources
- U.S. Food and Drug Administration — Drug Trials Snapshot: Lynkuet.
- U.S. Food and Drug Administration — Menopause treatment information.